Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

Last Close
Oct 11 04:00PM ET
1.44
Dollar change
+0.05
Percentage change
3.60
%
IndexRUT P/E- EPS (ttm)-0.21 Insider Own0.04% Shs Outstand125.76M Perf Week-2.04%
Market Cap181.09M Forward P/E- EPS next Y-0.27 Insider Trans0.00% Shs Float125.71M Perf Month-4.00%
Income-25.91M PEG- EPS next Q-0.06 Inst Own21.00% Short Float10.28% Perf Quarter2.86%
Sales0.00M P/S- EPS this Y7.29% Inst Trans35.49% Short Ratio20.05 Perf Half Y-13.25%
Book/sh0.64 P/B2.25 EPS next Y-21.35% ROA-26.68% Short Interest12.93M Perf Year105.71%
Cash/sh0.63 P/C2.27 EPS next 5Y- ROE-28.00% 52W Range0.62 - 2.31 Perf YTD63.64%
Dividend Est.- P/FCF- EPS past 5Y46.61% ROI-32.32% 52W High-37.66% Beta1.22
Dividend TTM- Quick Ratio14.35 Sales past 5Y0.00% Gross Margin- 52W Low132.26% ATR (14)0.07
Dividend Ex-Date- Current Ratio14.35 EPS Y/Y TTM17.34% Oper. Margin0.00% RSI (14)51.97 Volatility3.75% 4.95%
Employees12 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price5.50
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q38.02% Payout- Rel Volume0.56 Prev Close1.39
Sales Surprise- EPS Surprise16.67% Sales Q/Q- EarningsAug 12 BMO Avg Volume644.76K Price1.44
SMA200.00% SMA504.71% SMA20010.78% Trades Volume358,223 Change3.60%
Date Action Analyst Rating Change Price Target Change
Jan-26-18Initiated Maxim Group Buy $2
Oct-01-24 08:30AM
Sep-19-24 09:40AM
Sep-10-24 08:30AM
Sep-03-24 09:40AM
08:30AM
12:00PM Loading…
Aug-30-24 12:00PM
Aug-28-24 08:30AM
Aug-21-24 11:30AM
Aug-20-24 08:30AM
Aug-12-24 08:30AM
Jul-22-24 08:30AM
Jul-11-24 09:40AM
07:00AM
Jul-03-24 09:45AM
Jul-02-24 04:15PM
08:30AM Loading…
Jun-28-24 08:30AM
Jun-17-24 08:30AM
Jun-11-24 10:50AM
Jun-07-24 07:30AM
Jun-06-24 09:40AM
Jun-05-24 08:30AM
May-28-24 08:30AM
May-20-24 12:00PM
06:00AM
May-17-24 06:15AM
May-15-24 08:30AM
May-13-24 02:52PM
08:50AM
May-07-24 08:30AM
Apr-30-24 10:30AM
09:00AM Loading…
Apr-29-24 09:00AM
08:30AM
Apr-15-24 08:30AM
Apr-11-24 10:10AM
08:30AM
Apr-09-24 11:59AM
Apr-01-24 10:53PM
04:00PM
Mar-19-24 08:30AM
Mar-18-24 08:30AM
Mar-12-24 08:30AM
Mar-06-24 08:30AM
Feb-22-24 08:30AM
Feb-07-24 08:30AM
Jan-09-24 08:30AM
Dec-18-23 09:00AM
Dec-08-23 09:40AM
Dec-04-23 08:30AM
Nov-20-23 08:30AM
Nov-13-23 09:00AM
Nov-09-23 09:00AM
Oct-30-23 01:00PM
Oct-11-23 08:30AM
Sep-18-23 09:25AM
08:30AM
Aug-23-23 08:00AM
Aug-14-23 08:30AM
Aug-08-23 09:00AM
Jul-20-23 09:15AM
Jul-13-23 04:15PM
Jul-12-23 09:00AM
Jul-10-23 09:15AM
Jul-06-23 09:28PM
09:15AM
Jun-28-23 01:03PM
09:15AM
Jun-27-23 09:15AM
Jun-22-23 04:15PM
Jun-21-23 01:48PM
10:13AM
Jun-14-23 09:15AM
Jun-12-23 09:15AM
Jun-01-23 09:10AM
May-23-23 07:00AM
May-15-23 09:10AM
May-11-23 09:00AM
May-09-23 09:15AM
Apr-27-23 09:15AM
Mar-30-23 11:00AM
Mar-22-23 04:05PM
Mar-21-23 01:19PM
Mar-15-23 09:25AM
Feb-23-23 09:15AM
Feb-13-23 09:15AM
Jan-25-23 09:15AM
Dec-07-22 08:00AM
Nov-07-22 04:00PM
Nov-01-22 09:15AM
Oct-25-22 09:15AM
Oct-24-22 09:15AM
Oct-21-22 10:26AM
Sep-07-22 09:00AM
Aug-22-22 09:30AM
Aug-18-22 09:30AM
Aug-08-22 04:30PM
Jul-28-22 09:00AM
Jul-13-22 06:56PM
Jul-11-22 05:25PM
Jun-02-22 04:05PM
May-18-22 09:30AM
Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Finn JonathanDirectorApr 10 '24Buy1.7725,00044,25025,000Apr 11 04:05 PM
WEAVER GREGORY LFormer EVP, CFO, & DirectorNov 15 '23Sale0.6550,00032,50055Nov 17 04:01 PM